Has Felix Oviasu, MD received payments from drug or device companies?

Yes. Drug and device makers reported $150,080 in general payments to Felix Oviasu, MD across 85 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Felix Oviasu, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Felix Oviasu, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Felix Oviasu, MD

Cardiology · Garden City, NYNPI 1104898949

Payments from drug & device makers

What this record shows

This record is dominated by other: $144,082 of the $150,080 with a category attached, or 96.0%. Abbott accounts for 96.3% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2021 at $144,294 and has fallen 100.0% since, to $41 in 2024. Among cardiology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$150,080in general payments, 2019–2025

Across 85 payments — averaging $1765.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$145K
GE HealthCare$5K
Novartis$495
AstraZeneca$173
Boehringer Ingelheim$75
Johnson & Johnson$43
plus $45 from 2 others

What the payments were for

Speaking & faculty fees$4,7383%
Food & beverage$1,1851%
Education$750%
Other$144,08296%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	18	$144,511
GE HealthCare	1	$4,738
Novartis	49	$495
AstraZeneca	11	$173
Boehringer Ingelheim	1	$75
Johnson & Johnson	2	$43
Gilead	2	$29
E.r. Squibb & Sons, L.L.C.	1	$15

How this compares

$150,080 in reported general payments places this provider in the 95th percentile of 112 cardiology providers in New York.

See all cardiology providers in New York →

Medicare billing

Part B allowed, 2024

$278,041

Medicare patients

165

Services billed

2,406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	59	$82,215
XareltoRivaroxaban	57	$73,081
EntrestoSacubitril/Valsartan	32	$38,064
Ranolazine ErRanolazine	28	$2,273
Atorvastatin Calcium	124	$1,526
Metoprolol Succinate	103	$1,357
Isosorbide Mononitrate ErIsosorbide Mononitrate	79	$1,098
Nitroglycerin	42	$992
ClopidogrelClopidogrel Bisulfate	94	$980
Hydralazine Hcl	46	$910
Irbesartan	12	$838
Carvedilol	82	$776
Losartan Potassium	42	$742
Diltiazem 24hr Er (Cd)Diltiazem Hcl	31	$665
Labetalol Hcl	16	$659

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Johnson & JohnsonXarelto	$43	$73,08157 claims
NovartisEntresto	$495	$38,06432 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 112 cardiology providers in New York.

Other cardiology in Garden City

David D'agateSmithtown$69K
Michael SiegalNew York$43K
Michael AvaricioOzone Park$41K
Bimalkumar BrahmbhattAmityville$31K
Michael HappesSmithtown$30K
Meyer AbittanRoslyn$28K
Perminder GrewalStony Point$19K
Paul SapiaRoslyn$19K
Salim BaghdadiKew Gardens$18K
Ralph CaselnovaAmityville$16K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →